None listed
Conditions
Interventions
None listed
Sponsors
Yonsei University Health System, Gangnam Severance Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adult males or females aged 18 years or older. 2. Patients diagnosed with locally advanced or metastatic non-small cell lung cancer. 3. Patients diagnosed with histologically or cytologically confirmed mEGFR (+) adenocarcinoma of the lung. 4. Patients who have received treatment with a first-line EGFR-TKI approved in the country. 5. Patients who have experienced recurrence while on first-line EGFR-TKI therapy after the start date of the study. 6. Patients for whom the response to first-line EGFR-TKI therapy can be evaluated. 7. Patients who have provided consent for and undergone tissue biopsy, blood sample collection, and bronchoscopy for EGFR mutation confirmation. 8. Patients who have provided written consent for participation in the study.
Exclusion criteria
Exclusion criteria: Patients who discontinued treatment with first-generation or second-generation EGFR-TKIs for reasons other than disease progression. Patients for whom medical records are not available for review. Patients who cannot undergo all tests required for selection criterion 7) due to overall health status or other reasons. Patients for whom any form of intervention for cancer treatment occurred between bronchial washing fluid and blood sample collection. Individuals who have not consented to undergo testing and provide samples.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate, ORR | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-Free Survival (PFS), Duration of Response (DoR), Time to Tumor Progression (TTP) | — |
Countries
Korea, Republic of
Contacts
Public Contactchi young kim
Yonsei University Health System, Gangnam Severance Hospital
Outcome results
None listed